POCI — Precision Optics Corporation, Inc.

Precision Optics (POCI) Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Achieved a record $8.7 million for Q3 2026, up 108% year-over-year from $4.2 million and up from $7.4 million in Q2 2026.
• Production Revenue: Approximately $7.6 million, a significant increase from $3.3 million in the year-ago quarter.
• Adjusted EBITDA: Positive $300,000, a major milestone compared to negative $1.3 million in Q3 2025 and negative $1.5 million in Q2 2026.
• Gross Margin: Improved to 23.6% from 10% a year ago and 2.8% in the previous quarter.
• Net Loss: Reduced to $108,000 compared to $2.1 million in Q3 2025.
• Cash Position: Increased to $10.7 million from approximately $900,000 at the end of Q2 2026, bolstered by a $10 million public offering.

2. Strategic Updates and Business Highlights

• Production Improvements: Significant enhancements in manufacturing processes led to better efficiency and increased production yields, particularly in the aerospace program (97% yield) and single-use cystoscope program (over 90% yield).
• Key Programs: Continued strong performance from the aerospace program ($3.6 million revenue) and single-use cystoscope program ($2.2 million revenue). Ross Optical division also showed growth, reaching $1.3 million in revenue.
• New Orders: Announced a $3.5 million follow-on production order for the single-use ophthalmic endoscope program.
• Operational Leadership: Changes in operations leadership have positively impacted production efficiency and team performance.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased for fiscal 2026 to a range of $29 million to $31 million, up from previous guidance of $26 million to $28 million.
• Adjusted EBITDA Guidance: Revised to a range of negative $2.5 million to negative $2.7 million, reflecting improved operational performance.
• Future Programs: Anticipation of 5 to 6 new programs moving to production in fiscal 2027, including devices for small joint arthroscopy and robotic surgery.

4. Bad News, Challenges, or Points of Concern

• Customer Requested Slowdown: The aerospace program is expected to see a 15-20% production pullback in Q1 and Q2 of fiscal 2027 due to customer inventory issues.
• Yield Improvements: While yields have improved, the cystoscope program has not yet reached the targeted 95% yield, which may impact future profitability.
• Market Recognition: There is uncertainty regarding how quickly the industry will recognize the company's momentum and the potential for rapid revenue growth.

5. Notable Q&A Insights

• Revenue Expectations: Q4 revenue for aerospace and cystoscope programs is expected to remain stable, with a potential slowdown in aerospace production.
• Unity Platform: The Unity platform is anticipated to shorten the time frame for converting R&D into production, although current traction is slower than expected.
• Ross Optical Growth: The increase in sales for Ross Optical is viewed as sustainable, driven by new customers and a recovering market post-tariff uncertainties.
• Facility Capacity: Current facilities can potentially double in size, but updates are necessary to modernize equipment and improve efficiency.
• Profitability Outlook: The company expects to maintain breakeven levels in the near term, with potential for accelerated profitability as new programs ramp up.

Overall, Precision Optics reported a strong quarter with record revenues and significant operational improvements, though challenges remain with customer-driven production slowdowns and the need for further yield enhancements. The outlook is positive, with increased guidance and a robust pipeline of new programs.